Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances Proactive Mon, March 9, 2026 at 10:29 PM GMT+8 2 min read In this article: - LSTA -0.20%
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances Proactive uses images sourced from Shutterstock Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other serious diseases, announced that it has agreed to be acquired by privately held Kuva Labs.
Under the terms of a definitive agreement, Kuva will launch a tender offer to purchase all outstanding Lisata shares for $5 per share in cash at closing, plus one contingent value right (CVR) per share.
Shares of Lisata, which closed at $4.18 on Friday, surged almost 20% on Monday morning.
The CVR could provide an additional cash payment of $1 per share if a New Drug Application or similar regulatory filing for a product containing certepetide is submitted or formally accepted for review by the US Food and Drug Administration or another regulatory authority before the earlier of seven years after closing or termination of the CVR agreement.
If the milestone is not achieved within that period, no additional payment will be made under the CVR.
The deal is subject to customary closing conditions, including the tender of a majority of Lisata’s outstanding shares. The agreement does not include a financing condition.
The companies expect the transaction to close in the second quarter of 2026.
If the tender offer is completed, Kuva plans to acquire any remaining untendered shares and convertible securities through a second-step merger on the same terms.
Following completion of the transaction, Lisata will become part of Kuva, and its common stock will be delisted from the Nasdaq Capital Market.
Lisata’s board of directors unanimously approved the agreement after what the company described as a comprehensive strategic review conducted with the assistance of independent legal and financial advisors.
The board determined the transaction is advisable, fair to, and in the best interests of the company and its shareholders, and recommended that shareholders tender their shares into the offer.
Terms and Privacy Policy Privacy Dashboard More Info
